Elmwood Wealth Management Inc. Cuts Stock Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Elmwood Wealth Management Inc. decreased its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 76.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 468,240 shares of the company's stock after selling 1,557,500 shares during the quarter. Elmwood Wealth Management Inc. owned approximately 0.50% of Caribou Biosciences worth $428,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Centric Wealth Management acquired a new position in shares of Caribou Biosciences during the 4th quarter valued at about $27,000. Russell Investments Group Ltd. boosted its position in shares of Caribou Biosciences by 859.0% during the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock valued at $38,000 after acquiring an additional 21,416 shares during the last quarter. MetLife Investment Management LLC boosted its position in shares of Caribou Biosciences by 60.0% during the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock valued at $39,000 after acquiring an additional 9,148 shares during the last quarter. Diametric Capital LP acquired a new position in shares of Caribou Biosciences during the 4th quarter valued at about $42,000. Finally, US Bancorp DE raised its holdings in Caribou Biosciences by 3,524.2% in the 4th quarter. US Bancorp DE now owns 27,218 shares of the company's stock valued at $43,000 after buying an additional 26,467 shares during the period. Institutional investors and hedge funds own 77.51% of the company's stock.

Caribou Biosciences Trading Down 0.7%

CRBU traded down $0.01 on Friday, hitting $1.36. The company had a trading volume of 746,493 shares, compared to its average volume of 1,325,029. The firm has a market cap of $126.48 million, a P/E ratio of -0.84 and a beta of 2.48. Caribou Biosciences, Inc. has a 1 year low of $0.66 and a 1 year high of $3.00. The company's fifty day moving average price is $1.08 and its 200 day moving average price is $1.18.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.43). The company had revenue of $2.35 million for the quarter, compared to analyst estimates of $1.48 million. Caribou Biosciences had a negative net margin of 1,490.84% and a negative return on equity of 55.70%. On average, analysts predict that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CRBU. Wall Street Zen upgraded shares of Caribou Biosciences from a "sell" rating to a "hold" rating in a report on Saturday. HC Wainwright restated a "buy" rating and issued a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Caribou Biosciences has an average rating of "Moderate Buy" and a consensus target price of $8.50.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.